Meldopharm (Meldonium Dihydrate)

• Meldopharm (meldonium dihydrate) is employed in the anti‑ischemic pathway to support cardiac patients.
• Ischemic heart disease: reduces myocardial oxygen demand and improves energy utilization.
• Angina pectoris: alleviates chest pain episodes by enhancing cardiac metabolic efficiency.
• Heart failure: supports ventricular function and may improve exercise tolerance.

• Meldonium dihydrate inhibits γ‑butyrobetaine hydroxylase, the key enzyme in endogenous carnitine biosynthesis. By lowering intracellular carnitine levels, the drug reduces fatty‑acid transport into mitochondria, shifting myocardial energy production toward glucose oxidation, which requires less oxygen. This metabolic reprogramming enhances ATP generation under limited oxygen supply, protecting cardiac cells during ischemic episodes. The effect is dose‑dependent and contributes to improved myocardial perfusion and reduced arrhythmic risk.

Meldopharm may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Headache: transient cranial discomfort.
• Dizziness: occasional light‑headedness.
• Injection site reactions: erythema, pain or swelling at the infusion site.
• Fatigue: persistent tiredness.
• Elevated liver enzymes: transient increase in transaminases.

Serious or Rare Side Effects

• Cardiac arrhythmias: potentially life‑threatening rhythm disturbances.
• Severe hypotension: marked drop in blood pressure requiring intervention.
• Anaphylactic reaction: acute allergic response with respiratory compromise.
• Thrombocytopenia: reduced platelet count leading to bleeding risk.

When prescribing Meldopharm, clinicians should observe several precautionary measures to ensure patient safety.

• Renal impairment: adjust monitoring as reduced clearance may increase exposure.
• Hepatic dysfunction: evaluate liver function because metabolism may be altered.
• Concomitant anti‑arrhythmic drugs: monitor for additive electrophysiological effects.
• Pregnancy and lactation: use only if benefits outweigh potential risks, as data are limited.
• Hypersensitivity: discontinue immediately if signs of allergic reaction appear.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meldopharm can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP2D6 inhibitors: may increase plasma levels of meldonium, raising toxicity risk.
• Concurrent use with other metabolic modulators (e.g., trimetazidine): could amplify metabolic shifts and precipitate adverse cardiac events.

Moderate Interactions (Monitor Closely)

• Diuretics: monitor electrolytes and blood pressure as combined effects may cause hypotension.
• Anticoagulants: observe coagulation parameters because metabolic changes can affect drug clearance.
• Beta‑blockers: watch for additive bradycardia or reduced cardiac output.